<?xml version="1.0" encoding="UTF-8"?>
<ref id="CIT0033">
 <label>33</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Poulsen</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>William</surname>
    <given-names>A</given-names>
   </name>, 
   <name name-style="western">
    <surname>Blanchard</surname>
    <given-names>S</given-names>
   </name>, 
   <etal>et al.</etal>
  </person-group>
  <article-title>Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)</article-title>. 
  <source>J Mol Model</source>
  <year>2013</year>;
  <volume>19</volume>:
  <fpage>119</fpage>–
  <lpage>30</lpage>.
  <pub-id pub-id-type="pmid">22820730</pub-id>
 </mixed-citation>
</ref>
